1. Home
  2. DLO vs VKTX Comparison

DLO vs VKTX Comparison

Compare DLO & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DLocal Limited

DLO

DLocal Limited

HOLD

Current Price

$13.71

Market Cap

3.8B

ML Signal

HOLD

Logo Viking Therapeutics Inc.

VKTX

Viking Therapeutics Inc.

HOLD

Current Price

$29.97

Market Cap

4.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DLO
VKTX
Founded
2013
2012
Country
Uruguay
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
4.1B
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
DLO
VKTX
Price
$13.71
$29.97
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
7
Target Price
$17.25
$95.86
AVG Volume (30 Days)
1.4M
2.2M
Earning Date
05-14-2026
04-29-2026
Dividend Yield
1.45%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$41.00
N/A
Revenue Next Year
$26.98
N/A
P/E Ratio
$22.27
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.67
$22.96
52 Week High
$16.78
$43.15

Technical Indicators

Market Signals
Indicator
DLO
VKTX
Relative Strength Index (RSI) 58.58 33.86
Support Level $13.58 $23.08
Resistance Level $13.99 $35.85
Average True Range (ATR) 0.44 1.56
MACD 0.01 -0.53
Stochastic Oscillator 67.05 12.67

Price Performance

Historical Comparison
DLO
VKTX

About DLO DLocal Limited

DLocal Ltd is focused on making the complex simple, redefining the online payment experience in emerging markets. Through its technology platform, One dLocal, the company enables world-wide enterprise merchants to get paid (pay-in) and to make payments (pay-out) online in a safe and efficient manner. The company earns revenue from fees charged to merchants in connection with payment processing services for cross-border and local payment transactions. The company operates in a single operating segment, which is payment processing. The company's geographical segments include Latin America and Non-Latin America, with a majority of its revenue being generated from Brazil in the Latin America region.

About VKTX Viking Therapeutics Inc.

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Share on Social Networks: